Mode
Text Size
Log in / Sign up
Phase 3 Completed N=467 Randomized Quadruple-blind Treatment

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Source: ClinicalTrials.gov NCT02833844 ↗
Enrolled (actual)
467
Serious AEs
4.4%
Results posted
Jul 2020
Primary outcomePrimary: Percent Change From Baseline in LDL-C at Week 24 — 1.68; -55.23 percent change — p=< 0.0001
◆ Published Evidence
Highly cited
126citations · ~21 / year
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
The Cochrane database of systematic reviews · 2020 · Likely link

Summary

The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM) or placebo QM. The second part of the study is a 24-week open label extension period. During this time all participants will receive evolocumab QM. The clinical hypothesis is that subcutaneous evolocumab QM will be well tolerated and will result in greater reduction of low density lipoprotein cholesterol (LDL-C), defined as percent change from baseline at Week 24, compared with placebo QM in human immunodeficiency virus (HIV)-positive participants with hyperlipidemia or mixed dyslipidemia.

Linked Publications (4)

  • PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    The Cochrane database of systematic reviews · 2020 · 126 citations · Likely link
  • Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Journal of the American College of Cardiology · 2020 · 62 citations · Open access · Likely link
  • Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.
    AIDS (London, England) · 2022 · 16 citations · Open access · Likely link
  • Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics.
    American heart journal · 2020 · 11 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in LDL-C at Week 24
1.68; -55.23 < 0.0001 sig
SECONDARY
Change From Baseline in LDL-C at Week 24
-2.3; -77.5 < 0.0001 sig
SECONDARY
Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24
7.9; 73.3 < 0.0001 sig
SECONDARY
Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24
0.7; 72.5 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24
2.86; -48.07 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
2.59; -45.14 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Total Cholesterol (TC) at Week 24
2.34; -35.78 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24
10.35; -16.44 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Triglycerides at Week 24
13.21; -9.25 < 0.0001 sig
SECONDARY
Percent Change From Baseline in HDL-C at Week 24
2.73; 11.08 < 0.0001 sig
SECONDARY
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24
12.34; -9.81 < 0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Male or female ≥ 18 years of age
  • Known HIV infection with stable HIV therapy for ≥ 6 months
  • Cluster of differentiation 4 (CD4) ≥ 250 cells/mm^3 for ≥ 6 months
  • HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months
  • Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study
  • For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL
  • Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L)

Exclusion Criteria

  • Taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction
  • New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction (LVEF) < 30%
  • Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization
  • Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months
  • Type 1 diabetes, new-onset or poorly controlled type 2 diabetes
  • Uncontrolled hypertension
  • Taken a cholesteryl ester transfer protein inhibitor in the last 12 months
  • Moderate to severe renal dysfunction
  • Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of at least 1 year duration prior to randomization is allowed)
  • Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization

Other exclusion criteria may apply.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02833844) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search